Answers are grounded in this paper and cite their sources.
Hepatitis B was still a worldwide health problem. This study aimed to conducted a systematic review and meta-analysis to assess a more precise estimation of factors that influence the response to hepatitis B vaccine in adults. Our included studies examined seroprotection rates close to the end of vaccination schedules in healthy adult populations. This meta-analysis including 21053 adults in 37 articles showed that a significantly decreased response to hepatitis B vaccine appeared in adults (age ≥ 40) (RR:1.86, 95% CI:1.55-2.23), male adults (RR:1.40, 95% CI:1.22-1.61), BMI ≥ 25 adults (RR:1.56, 95% CI:1.12-2.17), smoker (RR:1.53, 95% CI:1.21-1.93), and adults with concomitant disease (RR:1.39, 95% CI:1.04-1.86). Meanwhile, we further found a decreased response to hepatitis B vaccine appeared in adults (age ≥ 30) (RR:1.77, 95% CI:1.48-2.10), and adults (age ≥ 60) (RR:1.30, 95% CI:1.01-1.68). However, there were no difference in response to hepatitis B vaccine both in alcoholic (RR:0.90, 95% CI:0.64-1.26) and 0-1-12 vs. 0-1-6 vaccination schedule (RR:1.39, 95% CI:0.41-4.67). Pooling of these studies recommended the sooner the better for adult hepatitis B vaccine strategy. More vaccine doses, supplemental/additional strengthening immunity should be emphasized on the susceptible population of increasing aged, male, BMI ≥ 25, smoking and concomitant disease. The conventional 0-1-6 vaccination schedule could be still worth to be recommended.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: